Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 (CPS) >= 10 status confers therapeutic sensitivity to Cisplatin, Fluorouracil, Pembrolizumab in patients with Esophageal Adenocarcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS >= 10.